Search results
Showing 2176 to 2190 of 2580 results for methods
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
Discontinued Reference number: GID-TA10151
Discontinued Reference number: GID-TA10154
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]
Discontinued Reference number: GID-TA10212
Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]
Discontinued Reference number: GID-TAG330
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
Discontinued Reference number: GID-TA10570
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
Discontinued Reference number: GID-TA10609
Discontinued Reference number: GID-TA11005
Discontinued Reference number: GID-TA10783
Discontinued Reference number: GID-TA10425
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued Reference number: GID-TA10327
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making
Evidence-based recommendations on ixekizumab (Taltz) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.
Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
Discontinued Reference number: GID-TA10081
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
Discontinued Reference number: GID-TA10088